Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
Phase II study of Durvalumab+/- Tremelimumab in patients with recurred metastatic head and neck squamous cell carcinoma
HNSCC|Head and Neck Neoplasms
DRUG: Durvalumab,Tremelimumab
Response rate (RR), RECIST1.1, 24months
•Progression-Free Survival (PFS), Disease progression is assessed by RECIST 1.1., 24months|•Overall Survival (OS), Overall Survival is defined as the time from first dose to death due to any cause. Through the follow-up within 30 days after study completion or termination of the last subject, death and date of death will be checked for subject alive during treatment period, 24months|•Toxicity, number of patients with treatment-related AE as assessed by NCI CTCAE version 4.03, 24months|•biomarker, NGS, nanostring technology, 24months
Open, multicenter, single arm, phase II, biomarker driven umbrella trial for head and neck squamous cell carcinoma